Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT02590523
Other study ID # 3
Secondary ID
Status Suspended
Phase Phase 3
First received
Last updated
Start date January 2023
Est. completion date January 2024

Study information

Verified date April 2022
Source Panhandle Eye Group, LLP
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine the safety (but not efficacy in preventing infection) of sterile-packaged and pre-loaded injectable solutions of both vancomycin and moxifloxacin at certain dosages and concentrations as prepared by a compounding pharmacy when used intracamerally at the time of cataract surgery.


Description:

Use of injectable prophylactic intracameral antibiotics during cataract surgery is gaining popularity worldwide due to the growing body of scientific evidence supporting its use. To date, there is no sterile-packaged antibiotic that has FDA approval for this indication. Surgeons using intracameral injectable antibiotics during cataract surgery must use existing pharmaceuticals off-label and/or rely on imprecise and sub-sterile compounding pharmacies to dispense these types of medications. Both of these scenarios may pose significant risk to patient safety. Description of the Treatment: Approximately 0.2 mL of either pre-loaded sterile vancomycin hydrochloride 1% solution (1 mg/0.1 mL of normal saline) or moxifloxacin hydrochloride 0.15% solution (150 μg/0.1 mL of normal saline) is injected into the eye with a blunt tip 30 gauge cannula through a small clear corneal incision as the last step in the cataract removal procedure. The purpose of the treatment is for prophylaxis against post-operative infections and endophthalmitis. Description of Effector Pharmaceuticals/Drugs: Vancomycin is a hydrophilic glycopeptide antibiotic that has been well studied in many different forms: intravenous injectable, oral tablet and even topical eye drop solutions. It is derived from Actinobacteria spp. Moxifloxacin is a synthetic fourth generation fluoroquinolone and has, likewise, been available in many forms including intravenous injectable, oral tablet and topical eye drop solutions. In this study, a contracted compounding pharmacy will produce the two pharmaceutical agents at the concentration/dosage mentioned above under the USP 797 guidelines. Therapeutic Mode of Action: The primary mode of action for vancomycin is inhibition of cell wall synthesis in gram positive bacteria. The molecule forms hydrogen bonds with terminal amnio acid moieties of the N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) polymer. The disruption to the polymerization and cross-linking of NAM-NAG complexes undermines the structural integrity of the bacterial organism leading to bacteriostasis and eventually cell death. The primary mode of action for moxifloxacin is inhibiting DNA gyrases, both type II topoisomerase and topoisomerase IV. These enzymes are essential for bacterial DNA replication to occur.


Recruitment information / eligibility

Status Suspended
Enrollment 500
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 100 Years
Eligibility Inclusion Criteria: - Diagnosis of visually significant cataract - Appropriate candidate for cataract surgery Exclusion Criteria: - Not willing to undergo an investigational treatment or are unable to cooperate well enough to safely perform the procedure under the protocol guidelines - Has known allergies to the pre-/intra-/post-operative medications or preservatives in the medications will also be excluded - Has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason - Has a known history of a condition which causes an immuno-compromised host state

Study Design


Intervention

Drug:
Vancomycin
Intracameral vancomycin injection during cataract surgery
Moxifloxacin
Intracameral moxifloxacin injection during cataract surgery
Placebo
Intracameral placebo injection with BSS during cataract surgery

Locations

Country Name City State
United States Rush Eye Amarillo Texas

Sponsors (1)

Lead Sponsor Collaborator
Panhandle Eye Group, LLP

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Endothelial cell count measured by specular microscopy specular microscopy 3 months
Other Rate of postoperative complication 3 months
Primary Occurrence of adverse event 3 months
Secondary Postoperative visual acuity measured by best spectacle corrected best spectacle corrected 3 months
See also
  Status Clinical Trial Phase
Completed NCT02573610 - Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery Phase 3
Completed NCT02910362 - Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines N/A
Recruiting NCT01193504 - Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Phase 4
Completed NCT01455233 - 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Phase 4
Completed NCT01199510 - Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery Phase 4
Completed NCT04146961 - The PanOptix Trifocal IOL: A Study of Patient Satisfaction, Visual Disturbances, and Uncorrected Visual Performance
Completed NCT00585975 - Efficacy and Safety of Bromfenac Ophthalmic Solution Phase 2
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Not yet recruiting NCT04131335 - Use of Prophylactic Lubricating Drops After Cataract Surgery N/A
Recruiting NCT05331690 - Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) Phase 4
Withdrawn NCT04563559 - PREFERENTIAL Study Phase 2/Phase 3
Completed NCT04732351 - Evaluation of the Active Sentry System During Cataract Surgery With the Centurion Phacoemulsifier
Completed NCT02128113 - RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Phase 2
Completed NCT03873454 - The Effects of Music on Perioperative Outcomes in Cataract Surgery N/A
Completed NCT04769856 - Impact of Non-fasting on Anxiety in Cataract Surgery N/A
Withdrawn NCT00604305 - Comperative Trial Between an Accommodative Iol and Monofocal Iol N/A
Completed NCT05925894 - Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma. N/A
Not yet recruiting NCT06136780 - Impact of Free Reading Glasses on Work and Visual Function Following Cataract Surgery in Honduras N/A
Completed NCT04633954 - Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery N/A
Completed NCT03644875 - Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber